Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol for inflammation-related anemia in hemodialysis patients receiving epoetin beta
2013-003855-38Phase 4Active
- Sponsor
- Miguel Giovanni Uriol Rivera
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of paricalcitol in anemia of inflammation (AI) and chronic kidney disease (CKD) (2 arms), sponsored by Miguel Giovanni Uriol Rivera. Primary endpoint: Percentage change in ESA dose at 6 months. Started Feb 2014; status: active.
02
Drugs
paricalcitol
03
Conditions
anemia of inflammation (AI)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2013-003855-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003855-38.